Project Grant HT94252310238

This Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $349,808 to Oncurie Inc. to continue development of a novel targeted radiopharmaceutical for imaging and potential therapy of ovarian cancer. The compound leverages the folate receptor overexpression in ovarian tumors to enable precision imaging, with future plans to incorporate cytotoxic radionuclides for targeted therapy. During the Phase I award period from Sep 2024...

This $400,000 Project Grant award from the National Cancer Institute's Cancer Treatment Research program (CFDA 93.395) supports Senex Biotechnology Inc.'s research to develop a novel nanoparticle formulation of the mediator kinase inhibitor SNX631-6 for the treatment of peritoneal ovarian cancer metastases. The goal is to optimize the nanoparticle formulation for improved pharmacokinetics and efficacy upon intraperitoneal (IP) administration, compared to oral delivery of the drug. Key activities...

This federal Project Grant award from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) provides $371,070 to Resonant Therapeutics, Inc. to develop a novel nectin-targeting antibody-drug conjugate (ADC) for the treatment of ovarian cancer. The funding will be used to refine the target patient population, determine the optimal payload, and establish preclinical dosing for the ADC. This represents an important advancement, as current ADC treatments for ovarian cancer are...

This $530,697 Project Grant from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research at the University of Pennsylvania to investigate the use of protein arginine methyltransferase (PRMT) inhibitors for treating high-grade serous ovarian cancer and triple-negative breast cancer. The key objectives are to: 1) characterize the molecular mechanisms of PRMT inhibitor mono- and combination therapies, 2) evaluate the therapeutic potential of PRMT inhibitors in...

This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) supports research to understand how mitochondrial stress responses in cancer cells influence the immune system's ability to fight ovarian cancer. The $936,746 award to Rutgers, The State University of New Jersey will utilize mouse models, reagents, and the university's extensive ovarian tumor bank to characterize the biology of the BTLP3A gene and its impact on generating protective anti-tumor...

This federal Project Grant award, valued at $744,575 and provided by the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research), supports research to define the genomic and biologic impact of Long Interspersed Element-1 (LINE-1) activity in fallopian tube epithelial cells and its potential contribution to the development of high-grade serous ovarian cancer. The research aims to determine if follicular fluid promotes LINE-1 expression in fallopian tube epithelial cells,...

This $396,061 Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research to assess the efficacy of a novel class of hypoxia-inducible factor (HIF) inhibitors as a potential treatment for renal cell carcinoma (RCC). The principal investigator has developed boron-based HIF inhibitors derived from the natural compound honokiol, which have demonstrated promising anti-angiogenic properties in vitro. This 2-year project aims to (1) determine...

This Project Grant award from the National Cancer Institute's Cancer Treatment Research program (CFDA 93.395) provides $800,888 to the University of Colorado-Denver to evaluate a combination therapy of the CLK/DYRK inhibitor cirtuvivint and the PARP inhibitor olaparib for treating platinum-resistant ovarian cancer patients with BRCA/HRD deficiencies. The research aims to establish the safety and tolerability of this combination therapy, as well as elucidate the mechanism behind the observed...

The National Cancer Institute (NCI) awarded a $151,000 Project Grant under the Cancer Cause and Prevention Research (CFDA 93.393) program to The Medical University of South Carolina (MUSC) to investigate the role of polyploid cancer cells in high-grade serous ovarian carcinoma (HGSOC). The project aims to: 1) Define essential genes for the polyploid cancer cell lifecycle and its critical transition stages using CRISPR-Cas9 screening, and 2) Determine the expression of putative polyploid cancer...

The University of California, Los Angeles (UCLA) was awarded a $220,894 Project Grant by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to identify novel molecular targets and compounds that can reverse the increased deformability, or 'mechanotype', of platinum-resistant ovarian cancer cells. The researchers will use a high-throughput cell filtration platform to screen large libraries of small molecules and conduct a genome-wide CRISPR-Cas9 screen to discover compounds...